Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ ...
Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.
Medical Device Network on MSN9d
Foresight announces trial launch for cHL treatment with ctDNA-based MRD testForesight Diagnostics and the University of Washington School of Medicine and Fred Hutch Cancer Center have announced the ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and ...
Adaptive Biotechnologies (ADPT) has launched an upgraded version of its clonoSEQ assay for measurable residual disease detection in diffuse ...
Melcor Developments Ltd. (TSX: MRD), an Alberta-based real estate development and asset management company, today reported results for the fourth quarter and ...
In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...
A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.
clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback